CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting
Abstract CAR-T therapy is rapidly reshaping the treatment paradigm of multiple myeloma (MM). At the 2025 ASH Annual Meeting, pivotal trials demonstrated marked efficacy across both relapsed/refractory and newly diagnosed settings. In KarMMa-3, a subgroup analysis of older patients (≥ 70 years) showe...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMC
2026-04-01
|
| Sarja: | Journal of Hematology & Oncology |
| Aiheet: | |
| Linkit: | https://doi.org/10.1186/s13045-026-01793-8 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|